289 results match your criteria: "Syreon Research Institute.[Affiliation]"
Front Pharmacol
December 2024
Syreon Research Institute, Budapest, Hungary.
Background: Non-adherence to medication remains a persistent and significant challenge, with profound implications for patient outcomes and the long-term sustainability of healthcare systems. Two decades ago, the World Health Organization (WHO) dedicated its seminal report to adherence to long-term therapies, catalysing notable changes that advanced both research and practice in medication adherence. The aim of this paper was to identify the most important progress made over the last 2 decades in medication adherence management and to initiate a discussion on future objectives, suggesting priority targets for the next 20 years.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Multiple chronic conditions reduce the quality of life and increase healthcare needs for people with diabetes mellitus (DM). This study aims to describe the prevalence of comorbidities associated with DM in the European Union (EU) at national and sub-national levels and to assess the utility of a comorbidity burden index. The study was carried out using microdata from European Health Interview Survey 2019 including adults aged 25 and older with DM from 26 EU member states (n = 20,042).
View Article and Find Full Text PDFCureus
November 2024
Health Economics, Semmelweis University, Center for Health Technology Assessment, Budapest, HUN.
Introduction Biologics are substantial in the treatment of different diseases; however, they can burden the healthcare systems due to their high cost. Biosimilars can help healthcare systems keep their financial sustainability and patients access to biological therapies. The research objective is to formulate a framework for integrating biosimilars in the private healthcare sector of the United Arab Emirates (UAE).
View Article and Find Full Text PDFLancet Reg Health Eur
January 2025
Syreon Research Institute, Budapest, Hungary.
J Hypertens
December 2024
Metabolic Centre, South-Buda Centrum Hospital - St. Imre University Teaching Hospital, Budapest, Hungary.
Objectives: Hypertension guidelines recommend the use of single-pill combinations (SPCs) of antihypertensive drugs to improve treatment persistence and blood pressure control. This study aimed to investigate the long-term effects of ramipril/amlodipine (R/A) SPC versus free equivalent dose combinations (FEC) on cardiovascular outcomes and treatment persistence.
Methods: This retrospective, observational study analysed the database of the Hungarian National Health Insurance Fund.
J Egypt Public Health Assoc
December 2024
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
BMJ Open
November 2024
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Background: In the evolving healthcare landscape of the United Arab Emirates (UAE), establishing cost-effectiveness thresholds (CETs) is pivotal to informing decision-makers about the value of health technologies.
Objective: This study aimed to establish CETs for the UAE that harmonise with international standards while reflecting the nation's unique healthcare needs and economic context.
Setting: United Arab Emirates.
Front Pharmacol
October 2024
Department of Family Medicine, Medication Adherence Research Centre, Medical University of Lodz, Lodz, Poland.
This study tackles the critical challenge of medication non-adherence in healthcare by pinpointing indicators related to medication adherence (IRMAs) across 39 European countries and Israel. Utilizing a structured expert survey methodology within the European Network to Advance Best Practices and Technology on Medication Adherence (ENABLE; COST Action CA19132), our research identified key country-specific IRMAs and collected data on these indicators to understand the multifaceted nature of medication adherence. The research was conducted in two phases: firstly, defining key IRMAs through a two-round expert survey, and secondly, gathering country-specific data on these IRMAs through literature reviews and additional expert surveys.
View Article and Find Full Text PDFFront Oncol
October 2024
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Background: The nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019.
Methods: Using data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospective study analyzed newly diagnosed malignancies between Jan 1, 2011, and Dec 31, 2019. Age-standardized incidence and mortality rates were calculated for all and for different tumor types using both the 1976 and 2013 European Standard Populations (ESP).
Expert Rev Pharmacoecon Outcomes Res
October 2024
Department of Pharmaceutical Sciences, Doctoral School of Semmelweis University, Budapest, Hungary.
Background: Atopic dermatitis (AD) imposes a hidden burden through its negative effects on quality of life and productivity. We aim to estimate this hidden burden in adults and adolescents in Central and Eastern European (CEE) countries.
Methods: We created a burden of disease model to quantify AD's hidden burden.
Front Med (Lausanne)
September 2024
Medication Adherence Research Centre, Department of Family Medicine, Medical University of Lodz, Lodz, Poland.
Introduction: This systematic review and meta-analysis aimed to analyze the adherence rate for conventional and biological disease-modifying antirheumatic drugs (DMARDs) utilizing different assessment measures.
Method: A systematic literature search was performed in four electronic databases, including PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL), covering the time frame from April 1970 to April 2023. Studies that present data on medication adherence among adult patients with rheumatoid arthritis (RA), specifically focusing on DMARDs (conventional or biological), were included in the analysis.
J Health Organ Manag
July 2024
Syreon Research Institute, Budapest, Hungary.
Purpose: Health technologies are advancing rapidly and becoming more expensive, posing a challenge for financing healthcare systems. Health technology assessment (HTA) improves the efficiency of resource allocation by facilitating evidence-informed decisions on the value of health technologies. Our study aims to create a customized HTA roadmap for Oman based on a gap analysis between the current and future status of HTA implementation.
View Article and Find Full Text PDFRadiol Oncol
September 2024
Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Background: Laser speckle coherence imaging (LSCI) is an emerging imaging modality that enables noninvasive visualization and assessment of tissue perfusion and microcirculation. In this article, we evaluated LSCI in imaging perfusion in clinical oncology through a systematic review of the literature.
Methods: The inclusion criterion for the literature search in PubMed, Web of Science and Scopus electronic databases was the use of LSCI in clinical oncology, meaning that all animal, phantom, , experimental, research and development, and purely methodological studies were excluded.
Nutr Rev
September 2024
Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
Objectives: The aim of this study was to analyze the modeling methodologies of fiscal policies on food with health or environmental outcomes.
Background: Evidence suggests that fiscal policies on food can contribute to addressing the growing burden of noncommunicable diseases and climate change. These policies should be modeled in advance to see the implications for the environment and health.
Cancers (Basel)
August 2024
Center for Health Technology Assessment, Semmelweis University, 1091 Budapest, Hungary.
We aimed to directly compare the cost-effectiveness of Hungarian (following the NELSON trial) and NLST screening protocols, two trials influencing lung-cancer-screening implementation internationally. A decision-analytic model analyzing the cost-effectiveness of Hungarian protocols was manipulated to reflect the protocols of the NLST, while maintaining features specific to the Hungarian healthcare setting. In the Hungarian protocol, there are three possible outcomes to the initial round of screening, positive, negative, and indeterminate, indicating an uncertain degree of suspicion for lung cancer.
View Article and Find Full Text PDFJ Sch Psychol
October 2024
MTA-PTE Innovative Health Pedagogy Research Group, Szigeti utca 12, Pécs H-7624, Hungary; Department of Public Health Medicine, School of Medicine, University of Pécs, Szigeti utca 12, Pécs H-7624, Hungary; Bethesda Children's Hospital, Bethesda utca 3, Budapest H-1146, Hungary.
The level of psychological stress in children and adolescents has increased rapidly over the past decade. The aim of the present meta-analysis was to evaluate the effectiveness of school-based intervention programs targeting stress management and coping/resilience in school-aged children. The present study used more rigorous selection criteria than previous meta-analyses by only including randomized controlled trials to increase the validity of the meta-analysis.
View Article and Find Full Text PDFExpert Rev Pharmacoecon Outcomes Res
November 2024
Korea Institute for Pharmaceutical Policy Affairs, Seoul, South Korea.
Eur J Public Health
December 2024
NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, REAL, CCAL, NOVA University Lisbon, Lisbon, Portugal.
Cureus
July 2024
Health Economics, Syreon Research Institute, Budapest, HUN.
Background The scarcity of resources restricts healthcare financing decisions, affecting the population's health. Health technology assessment (HTA) balances restricted budgets with the best possible health outcomes. We aim to characterize the current status of HTA in Algeria and describe the future directions for HTA implementation according to the priorities set by local stakeholders.
View Article and Find Full Text PDFDiabetes Res Clin Pract
October 2024
Institute of Preventive Medicine and Public Health, Faculty of Medicine, Semmelweis University, Üllői út 26, Budapest H-1085, Hungary; Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Üllői út 26, Budapest H-1085, Hungary; UCL Brain Sciences, University College London, 149 Tottenham Court Road, London W1T 7NF, United Kingdom.
Aims: To estimate prevalence of diagnosed (dDM) and undiagnosed diabetes (uDM) in Hungary and investigate determinants of uDM.
Methods: Data was obtained from the nationally representative H-UNCOVER study. As laboratory measurements were available for 11/19 Hungarian counties, n = 5,974/17,787 people were eligible.
Value Health
November 2024
Science Policy and Research Program, National Institute for Health and Care Excellence (NICE), United Kingdom.
J Cardiovasc Dev Dis
June 2024
Syreon Research Institute, 1142 Budapest, Hungary.
Despite the availability of affordable pharmaceuticals treating cardiovascular diseases (CVDs), many of the risk factors remain poorly controlled. Fixed-dose combinations (FDCs), a form of incremental innovation, have already demonstrated improvements over combinations of single medicines in adherence and hard clinical endpoints. Nevertheless, there are many barriers related to the wider use of FDCs in CVDs.
View Article and Find Full Text PDFExpert Rev Pharmacoecon Outcomes Res
September 2024
Department of Health Services Research, CAPHRI Care & Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
Value Health Reg Issues
November 2024
Senior Researcher, Syreon Research Institute, Buenos Aires, Argentina.
Objectives: The World Health Organization provides 10 specific guidelines for managing the prices of pharmaceutical products. Many of those are widely known and used such as reference pricing, value-based pricing, price transparency, and tendering. Less attention and knowledge is concentrated in markup regulation across the pharmaceutical supply chain and distribution and in tax exemptions or reductions.
View Article and Find Full Text PDF